by Sarah Moniz | Dec 27, 2019 | News
Providence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and...
by Sarah Moniz | Dec 20, 2019 | News
Providence, R.I., December 17, 2019 EpiVax, Inc. (“EpiVax”), the home of “fearless science”, announces it will renew their company-wide commitment to “improving human health everywhere” in the new decade (2020). EpiVax has a greater than 20-year tradition of corporate...
by Sarah Moniz | Oct 16, 2018 | Events
Here are commemorative photos from our event. Thank you to all the speakers and participants for making our 2018 Immunogenicity and Tolerance seminar a successful one! We will see you next year! This seminar will center around current translational research in the...
by Sarah Moniz | Sep 26, 2018 | Events
UPDATE: Here are commemorative photos from our event. Thank you to all the speakers and participants for making the 2018 seminar a success. See you next year! The Westin Immunogenicity Seminar is a unique forum for industry and academic professionals to share ideas,...
by Sarah Moniz | Jun 13, 2018 | News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
